Assesment of Risk Factors for Tardive Dyskinesia
- PMID: 32733110
- PMCID: PMC7377543
Assesment of Risk Factors for Tardive Dyskinesia
Abstract
Objective: Aim of the study is to evaluate sociodemographic and clinical features that may be associated with the development of Tardive dyskinesia (TD).
Methods: 80 patients attending an outpatient psychiatry clinic in Istanbul, Turkey were divided into TD (n = 50) and control groups (CG) (n = 30). Sociodemographic and clinical data was collected through face-to-face interviews and a retrospective search of medical records.
Results: There was a significant difference between TD and control group (CG) in terms of mean; onset of psychiatric disease at or after 35 years of age; first use of APD at or after 35 years of age; use of long-acting injectable APD; history of extrapyramidal side-effects; history of akathisia and family history of psychiatric disease. There was no significant difference between the two groups in terms of DSM- IV-based psychiatric diagnosis distributions, the existence of complete recovery periods during the course of the disease; total duration of APD use for at least 10 years; APD holidays; regular APD use; history of ECT and smoking or alcohol and substance abuse/addiction.
Conclusion: Advancing age seemed to be the most significant risk factor in the development of TD. Clinicians need to be cautious about TD when prescribing APD for elderly patients.
Keywords: Tardive dyskinesia; antipsychotic drugs; drug-induced movement disorders.
Copyright © 1964–2019 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.
Conflict of interest statement
Conflicts of interest The authors have no conflicts of interest
Similar articles
-
[Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].Encephale. 2016 Jun;42(3):248-54. doi: 10.1016/j.encep.2015.12.021. Epub 2016 Feb 26. Encephale. 2016. PMID: 26922134 Review. French.
-
Clinical risk factors for the development of tardive dyskinesia.J Neurol Sci. 2018 Jun 15;389:21-27. doi: 10.1016/j.jns.2018.02.012. Epub 2018 Feb 5. J Neurol Sci. 2018. PMID: 29439776 Review.
-
An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.Schizophr Res. 2005 Sep 15;77(2-3):129-39. doi: 10.1016/j.schres.2005.03.015. Schizophr Res. 2005. PMID: 15913962 Clinical Trial.
-
A descriptive analysis of spontaneous reports of antipsychotic-induced tardive dyskinesia and other extrapyramidal symptoms in the Japanese Adverse Drug Event Report database.Neuropsychopharmacol Rep. 2024 Mar;44(1):221-226. doi: 10.1002/npr2.12385. Epub 2023 Oct 26. Neuropsychopharmacol Rep. 2024. PMID: 37884014 Free PMC article.
-
Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V.J Clin Psychiatry. 2006 Dec;67(12):1920-7. doi: 10.4088/jcp.v67n1212. J Clin Psychiatry. 2006. PMID: 17194270
Cited by
-
Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan.Ther Adv Psychopharmacol. 2022 Dec 26;12:20451253221139608. doi: 10.1177/20451253221139608. eCollection 2022. Ther Adv Psychopharmacol. 2022. PMID: 36601351 Free PMC article. Review.
-
Seventy Years of Antipsychotic Development: A Critical Review.Biomedicines. 2023 Jan 4;11(1):130. doi: 10.3390/biomedicines11010130. Biomedicines. 2023. PMID: 36672638 Free PMC article. Review.
-
Tardive Dyskinesia in Older Persons Taking Antipsychotics.Neuropsychiatr Dis Treat. 2021 Oct 14;17:3127-3134. doi: 10.2147/NDT.S328301. eCollection 2021. Neuropsychiatr Dis Treat. 2021. PMID: 34703232 Free PMC article. Review.
-
Correlation of Blood Biochemical Markers with Tardive Dyskinesia in Schizophrenic Patients.Dis Markers. 2022 Mar 8;2022:1767989. doi: 10.1155/2022/1767989. eCollection 2022. Dis Markers. 2022. PMID: 35299866 Free PMC article.
References
-
- Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. J Clinical Psychiatry. 2017;78(3):264–278. - PubMed
-
- Nalbant A, Can A, Burhan HS, Cansız A, Yavuz KF, Delice MA, et al. Tardive dyskinesia in long term hospitalized patients with schizophrenia. Dusunen Adam The Journal of Psychiatry and Neurological Sciences. 2016;29:259–265.
-
- Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull. 1993;119:303–315. - PubMed
-
- Achalia RM, Chaturvedi SK, Desai G, Rao GN, Prakash O. Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia. Asian J Psychiatr. 2014;9:31–35. - PubMed
-
- Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JA. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155(11):1521–1528. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources